Top ▲

L-type amino acid transporter 1

Click here for help

Immunopharmacology Ligand target has curated data in GtoImmuPdb

Target id: 896

Nomenclature: L-type amino acid transporter 1

Abbreviated Name: LAT1

Systematic Nomenclature: SLC7A5

Family: SLC7 family

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 12 507 16q24.2 SLC7A5 solute carrier family 7 member 5
Mouse 12 512 8 Slc7a5 solute carrier family 7 (cationic amino acid transporter, y+ system), member 5
Rat 12 512 19q12 Slc7a5 solute carrier family 7 member 5
Previous and Unofficial Names Click here for help
4F2 light chain | 4F2LC | integral membrane protein E16 | Large neutral amino acids transporter small subunit 1 | CD98 | MPE16 | solute carrier family 7 (amino acid transporter light chain, L system), member 5 | TA1 | solute carrier family 7 member 5 | tumor-associated protein 1 | solute carrier family 7 (cationic amino acid transporter, y+ system), member 5 | solute carrier family 7 (cationic amino acid transporter
Database Links Click here for help
Specialist databases
Bioparadigms SLC Tables SLC7A5 (Hs)
Other databases
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
Selected 3D Structures Click here for help
Image of receptor 3D structure from RCSB PDB
Description:  LAT1-CD98hc complex bound to MEM-108 Fab
Resolution:  0.0Å
Species:  Human
References:  10
Image of receptor 3D structure from RCSB PDB
Description:  LAT1-4F2hc complex incubated with JPH203 (KYT-0353)
Ligand:  KYT-0353
Resolution:  0.0Å
Species:  Human
References:  20

Download all structure-activity data for this target as a CSV file go icon to follow link

Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
KYT-0353 Small molecule or natural product Primary target of this compound Hs Inhibition - - 14
Immunopharmacology Comments
LAT1 has been identified as being a key transporter of the essential amino acids [3] that are required to support the nutritional demands of activated human T cells when mounting an immune response, and LAT1 expression is upregulated to meet this demand [2,13,18]. These findings suggest LAT1 as a novel target for the development of drugs with immuno-suppressive potential.
Immuno Process Associations
Immuno Process:  Inflammation
Immuno Process:  Chemotaxis & migration
General Comments
LAT1 is a key transporter of essential amino acids [3]. LAT1 is used by many types of cancer cells to meet their high nutritional requirements [4,11]. Consequently, LAT1 inhbitors that would functionally starve cancers of essential nutrients, are being designed as potential anti-cancer therapeutics [1,5,7-9,12], and as adjuncts which enhance the efficacy of conventional chemotherapeutics [19]. LAT1 expression on cancer cells is also being used to target anti-cancer drugs to tumours using so-called 'LAT1-utilizing prodrugs' [6,16], and of particular clinical interest is the ability of some of these prodrugs to cross the blood-brain-barrier and the benefit this could bring to the treatment of brain tumours [15,17].


Show »

1. Hayashi K, Anzai N. (2017) Novel therapeutic approaches targeting L-type amino acid transporters for cancer treatment. World J Gastrointest Oncol, 9 (1): 21-29. [PMID:28144396]

2. Hayashi K, Jutabha P, Endou H, Sagara H, Anzai N. (2013) LAT1 is a critical transporter of essential amino acids for immune reactions in activated human T cells. J Immunol, 191 (8): 4080-5. [PMID:24038088]

3. Hayashi K, Jutabha P, Kamai T, Endou H, Anzai N. (2014) LAT1 is a central transporter of essential amino acids in human umbilical vein endothelial cells. J Pharmacol Sci, 124 (4): 511-3. [PMID:24671056]

4. Hayashi K, Jutabha P, Maeda S, Supak Y, Ouchi M, Endou H, Fujita T, Chida M, Anzai N. (2016) LAT1 acts as a crucial transporter of amino acids in human thymic carcinoma cells. J Pharmacol Sci, 132 (3): 201-204. [PMID:27567475]

5. Huttunen KM, Gynther M, Huttunen J, Puris E, Spicer JA, Denny WA. (2016) A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells. J Med Chem, 59 (12): 5740-51. [PMID:27253989]

6. Huttunen KM, Huttunen J, Aufderhaar I, Gynther M, Denny WA, Spicer JA. (2016) L-Type amino acid transporter 1 (lat1)-mediated targeted delivery of perforin inhibitors. Int J Pharm, 498 (1-2): 205-16. [PMID:26705152]

7. Imai H, Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, Sunaga N, Ishizuka T, Nagamori S, Promchan K et al.. (2010) Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. Anticancer Res, 30 (12): 4819-28. [PMID:21187458]

8. Kanai Y. (2022) Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics. Pharmacol Ther, 230: 107964. [PMID:34390745]

9. Kongpracha P, Nagamori S, Wiriyasermkul P, Tanaka Y, Kaneda K, Okuda S, Ohgaki R, Kanai Y. (2017) Structure-activity relationship of a novel series of inhibitors for cancer type transporter L-type amino acid transporter 1 (LAT1). J Pharmacol Sci, 133 (2): 96-102. [PMID:28242177]

10. Lee Y, Wiriyasermkul P, Jin C, Quan L, Ohgaki R, Okuda S, Kusakizako T, Nishizawa T, Oda K, Ishitani R et al.. (2019) Cryo-EM structure of the human L-type amino acid transporter 1 in complex with glycoprotein CD98hc. Nat Struct Mol Biol, 26 (6): 510-517. [PMID:31160781]

11. Marshall AD, van Geldermalsen M, Otte NJ, Anderson LA, Lum T, Vellozzi MA, Zhang BK, Thoeng A, Wang Q, Rasko JE et al.. (2016) LAT1 is a putative therapeutic target in endometrioid endometrial carcinoma. Int J Cancer, 139 (11): 2529-39. [PMID:27486861]

12. Napolitano L, Scalise M, Koyioni M, Koutentis P, Catto M, Eberini I, Parravicini C, Palazzolo L, Pisani L, Galluccio M et al.. (2017) Potent inhibitors of human LAT1 (SLC7A5) transporter based on dithiazole and dithiazine compounds for development of anticancer drugs. Biochem Pharmacol, 143: 39-52. [PMID:28709952]

13. Nii T, Segawa H, Taketani Y, Tani Y, Ohkido M, Kishida S, Ito M, Endou H, Kanai Y, Takeda E et al.. (2001) Molecular events involved in up-regulating human Na+-independent neutral amino acid transporter LAT1 during T-cell activation. Biochem J, 358 (Pt 3): 693-704. [PMID:11535130]

14. Oda K, Hosoda N, Endo H, Saito K, Tsujihara K, Yamamura M, Sakata T, Anzai N, Wempe MF, Kanai Y et al.. (2010) L-type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Sci, 101 (1): 173-9. [PMID:19900191]

15. Papin-Michault C, Bonnetaud C, Dufour M, Almairac F, Coutts M, Patouraux S, Virolle T, Darcourt J, Burel-Vandenbos F. (2016) Study of LAT1 Expression in Brain Metastases: Towards a Better Understanding of the Results of Positron Emission Tomography Using Amino Acid Tracers. PLoS ONE, 11 (6): e0157139. [PMID:27276226]

16. Park K. (2017) Insight into brain-targeted drug delivery via LAT1-utilizing prodrugs. J Control Release, 261: 368. [PMID:28780138]

17. Puris E, Gynther M, Huttunen J, Petsalo A, Huttunen KM. (2017) L-type amino acid transporter 1 utilizing prodrugs: How to achieve effective brain delivery and low systemic exposure of drugs. J Control Release, 261: 93-104. [PMID:28662899]

18. Ren W, Liu G, Yin J, Tan B, Wu G, Bazer FW, Peng Y, Yin Y. (2017) Amino-acid transporters in T-cell activation and differentiation. Cell Death Dis, 8 (3): e2655. [PMID:28252650]

19. Yamauchi K, Sakurai H, Kimura T, Wiriyasermkul P, Nagamori S, Kanai Y, Kohno N. (2009) System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line. Cancer Lett, 276 (1): 95-101. [PMID:19058911]

20. Yan R, Zhao X, Lei J, Zhou Q. (2019) Structure of the human LAT1-4F2hc heteromeric amino acid transporter complex. Nature, 568 (7750): 127-130. [PMID:30867591]

How to cite this page